JPWO2021216139A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021216139A5
JPWO2021216139A5 JP2022563366A JP2022563366A JPWO2021216139A5 JP WO2021216139 A5 JPWO2021216139 A5 JP WO2021216139A5 JP 2022563366 A JP2022563366 A JP 2022563366A JP 2022563366 A JP2022563366 A JP 2022563366A JP WO2021216139 A5 JPWO2021216139 A5 JP WO2021216139A5
Authority
JP
Japan
Prior art keywords
medicament
kinase inhibitor
rho kinase
patient
alzheimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022563366A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023523706A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/012588 external-priority patent/WO2021216139A1/fr
Publication of JP2023523706A publication Critical patent/JP2023523706A/ja
Publication of JPWO2021216139A5 publication Critical patent/JPWO2021216139A5/ja
Pending legal-status Critical Current

Links

JP2022563366A 2020-04-23 2021-01-08 アルツハイマー病を治療するためのｒｈｏキナーゼ阻害剤の使用方法 Pending JP2023523706A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063014272P 2020-04-23 2020-04-23
US63/014,272 2020-04-23
PCT/US2021/012588 WO2021216139A1 (fr) 2020-04-23 2021-01-08 Méthodes d'utilisation d'inhibiteurs de la rho kinase pour traiter la maladie d'alzheimer

Publications (2)

Publication Number Publication Date
JP2023523706A JP2023523706A (ja) 2023-06-07
JPWO2021216139A5 true JPWO2021216139A5 (fr) 2024-01-11

Family

ID=78269840

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022563366A Pending JP2023523706A (ja) 2020-04-23 2021-01-08 アルツハイマー病を治療するためのｒｈｏキナーゼ阻害剤の使用方法

Country Status (7)

Country Link
US (2) US20230190765A1 (fr)
EP (1) EP4138842A4 (fr)
JP (1) JP2023523706A (fr)
CN (1) CN115996728A (fr)
CA (1) CA3175183A1 (fr)
MX (1) MX2022012957A (fr)
WO (1) WO2021216139A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115916187A (zh) * 2020-03-25 2023-04-04 乌尔塞制药公司 治疗蛋白病相关的游荡的方法
WO2023097151A1 (fr) 2021-11-29 2023-06-01 Woolsey Pharmaceuticals, Inc. Procédés de traitement d'agitation et d'autres symptômes comportementaux associés à la démence
CN115998736B (zh) * 2023-03-28 2023-06-23 中国人民解放军军事科学院军事医学研究院 Y-27632在特异性抑制幻觉作用中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005117896A1 (fr) * 2004-06-03 2005-12-15 Schering Aktiengesellschaft Formulations contenant du fasudil, une matrice et une enveloppe
WO2006094072A2 (fr) * 2005-03-01 2006-09-08 Functional Neuroscience Inc. Methode de traitement de troubles cognitifs au moyen d'une neuromodulation
CA2659289A1 (fr) * 2006-08-10 2008-02-14 Translational Genomics Research Institute Composes pour ameliorer l'apprentissage et la memoire
KR20110014183A (ko) * 2008-05-12 2011-02-10 엠네스틱스, 인코포레이티드 학습 및 기억을 개선시키기 위한 화합물
WO2013135596A1 (fr) * 2012-03-12 2013-09-19 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Inhibiteurs de kinase rho s'utilisant dans le traitement de la sclérose latérale amyotrophique
CN115103672A (zh) * 2020-01-09 2022-09-23 悟而喜制药公司 治疗与皮质性痴呆相关的游荡的方法
CN115916187A (zh) * 2020-03-25 2023-04-04 乌尔塞制药公司 治疗蛋白病相关的游荡的方法
MX2023004523A (es) * 2020-10-22 2023-05-08 Woolsey Pharmaceuticals Inc Metodos de tratamiento de tauopatias de 4 repeticiones.

Similar Documents

Publication Publication Date Title
KR101125462B1 (ko) 모다피닐의 제약 제제
US4507323A (en) Treatment of psychosexual dysfunctions
US11318144B2 (en) Compositions and methods for treating Alzheimer's disease and Parkinson's disease
JP2002524498A (ja) 機能性及び／又は器質性痛み症候群の治療のための製薬組成物の調製のためのアセチルコリンエステラーゼ阻害剤の使用
JPH0667841B2 (ja) 恐慌障害の軽減剤
US6075028A (en) Method of treating Tourette's syndrome and related CNS disorders
WO2021262196A1 (fr) Compositions et méthodes de traitement de la maladie d'alzheimer et de la maladie de parkinson
JPWO2008090736A1 (ja) アルツハイマー型認知症の予防及び治療のための医薬
JPH0667842B2 (ja) 基本的うつ病を軽減するためのうつ病治療剤
US5897864A (en) Method for treating sexual dysfunction disorders with compositions containing ginkgo biloba
US20050256131A1 (en) Pharmaceutical active substance combination and the use thereof
JPWO2021216139A5 (fr)
RU2003127718A (ru) Применение флумазенила в производстве лекарственного средства для лечения кокаиновой зависимости
IE58734B1 (en) Use of propiophenone compounds
KR100692235B1 (ko) 안지오텐신 ⅱ 길항물질의 신규한 용도
JP4166955B2 (ja) ウイルス疾患を処置するためのビュープロピオン
AU2001274765A1 (en) New use of angiotensin II antagonists
RU2369393C2 (ru) Применение окскарбазепина для лечения диабетической нейропатической боли и для улучшения сна
US6589996B2 (en) Treatment of disorders relating to the serotonergic system
JPWO2021257122A5 (fr)
CA2469702A1 (fr) Utilisation de la darifenacine dans le traitement de mictions imperieuses induites par une vessie hyperactive
JP2024505246A (ja) 神経変性認知障害を治療するための、コリンエステラーゼ阻害薬と四級アンモニウム抗ムスカリン剤との固定用量配合剤
CA2231557A1 (fr) Compositions a base de melatonine et d'antalgiques et utilisations
WO2001074364A2 (fr) Utilisation de galantamine dans le traitement de la maladie d'alzheimer ciblant la cause fondamentale de la maladie
JPWO2021178737A5 (fr)